AN2 Therapeutics Initiates First-in-Human Clinical Trial for Potential Chagas Disease Cure, AN2-502998

Reuters

08/12

AN2 <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Initiates First-in-Human Clinical Trial for Potential Chagas Disease Cure, AN2-502998

AN2 Therapeutics Inc. has announced the commencement of its first-in-human clinical trial for the drug candidate AN2-502998, intended for the treatment of chronic Chagas disease. This Phase 1 trial aims to evaluate the safety, tolerability, and pharmacokinetics of the oral drug in healthy volunteers. Preclinical studies in nonhuman primates have indicated AN2-502998's potential to cure chronic Chagas disease. With no FDA-approved treatment available for adults with the disease, this development is significant. The company plans to complete Phase 1 dosing by the end of 2025. In collaboration with the Drugs for Neglected Diseases initiative, AN2 Therapeutics is also preparing for a Phase 2 trial, anticipated to start in 2026, with data expected in 2027. Results from the current Phase 1 trial have not yet been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AN2 Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250812650698) on August 12, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2558649905"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2558649905\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2558649905?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-12 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2558649905","market":"us","top_or_hot":-1,"title":"AN2 Therapeutics Initiates First-in-Human Clinical Trial for Potential Chagas Disease Cure, AN2-502998","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      AN2 <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Initiates First-in-Human Clinical Trial for Potential Chagas Disease Cure, AN2-502998\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        AN2 Therapeutics Inc. has announced the commencement of its first-in-human clinical trial for the drug candidate AN2-502998, intended for the treatment of chronic Chagas disease. This Phase 1 trial aims to evaluate the safety, tolerability, and pharmacokinetics of the oral drug in healthy volunteers. Preclinical studies in nonhuman primates have indicated AN2-502998's potential to cure chronic Chagas disease. With no FDA-approved treatment available for adults with the disease, this development is significant. The company plans to complete Phase 1 dosing by the end of 2025. In collaboration with the Drugs for Neglected Diseases initiative, AN2 Therapeutics is also preparing for a Phase 2 trial, anticipated to start in 2026, with data expected in 2027. Results from the current Phase 1 trial have not yet been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AN2 Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250812650698) on August 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AN2 Therapeutics Initiates First-in-Human Clinical Trial for Potential Chagas Disease Cure, AN2-502998</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAN2 Therapeutics Initiates First-in-Human Clinical Trial for Potential Chagas Disease Cure, AN2-502998\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-08-12 19:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      AN2 <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Initiates First-in-Human Clinical Trial for Potential Chagas Disease Cure, AN2-502998\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        AN2 Therapeutics Inc. has announced the commencement of its first-in-human clinical trial for the drug candidate AN2-502998, intended for the treatment of chronic Chagas disease. This Phase 1 trial aims to evaluate the safety, tolerability, and pharmacokinetics of the oral drug in healthy volunteers. Preclinical studies in nonhuman primates have indicated AN2-502998's potential to cure chronic Chagas disease. With no FDA-approved treatment available for adults with the disease, this development is significant. The company plans to complete Phase 1 dosing by the end of 2025. In collaboration with the Drugs for Neglected Diseases initiative, AN2 Therapeutics is also preparing for a Phase 2 trial, anticipated to start in 2026, with data expected in 2027. Results from the current Phase 1 trial have not yet been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AN2 Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250812650698) on August 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nNDLzTl8w:1","article_id":"2558649905","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2558649905","pubTimestamp":1754996489,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"AN2 Therapeutics Inc. has announced the commencement of its first-in-human clinical trial for the drug candidate AN2-502998, intended for the treatment of chronic Chagas disease. This Phase 1 trial aims to evaluate the safety, tolerability, and pharmacokinetics of the oral drug in healthy volunteers. Preclinical studies in nonhuman primates have indicated AN2-502998's potential to cure chronic Chagas disease. With no FDA-approved treatment available for adults with the disease, this development is significant. The company plans to complete Phase 1 dosing by the end of 2025. In collaboration with the Drugs for Neglected Diseases initiative, AN2 Therapeutics is also preparing for a Phase 2 trial, anticipated to start in 2026, with data expected in 2027. Results from the current Phase 1 trial have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, th","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","ANTX":"AN2 Therapeutics, Inc."},"translate_title":"AN2 Therapeutics启动首个潜在治疗恰加斯病的人体临床试验AN2-502998","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANTX":0.9},"content_text":"AN2 Therapeutics Initiates First-in-Human Clinical Trial for Potential Chagas Disease Cure, AN2-502998\n    \n\n        AN2 Therapeutics Inc. has announced the commencement of its first-in-human clinical trial for the drug candidate AN2-502998, intended for the treatment of chronic Chagas disease. This Phase 1 trial aims to evaluate the safety, tolerability, and pharmacokinetics of the oral drug in healthy volunteers. Preclinical studies in nonhuman primates have indicated AN2-502998's potential to cure chronic Chagas disease. With no FDA-approved treatment available for adults with the disease, this development is significant. The company plans to complete Phase 1 dosing by the end of 2025. In collaboration with the Drugs for Neglected Diseases initiative, AN2 Therapeutics is also preparing for a Phase 2 trial, anticipated to start in 2026, with data expected in 2027. Results from the current Phase 1 trial have not yet been presented.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AN2 Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250812650698) on August 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}